Department of Veterinary Clinical Sciences, The Royal Veterinary College, Hertfordshire, UK.
J Vet Intern Med. 2012 Mar-Apr;26(2):302-11. doi: 10.1111/j.1939-1676.2012.00894.x. Epub 2012 Feb 28.
Identification of factors associated with decreased survival in dogs with degenerative mitral valve disease (DMVD) will allow more accurate prognosis. N-terminal pro-B-type natriuretic peptide (NT-proBNP) is negatively associated with survival in dogs with DMVD. In human patients, multimarker strategies provide superior risk stratification compared with single markers.
High-sensitivity cardiac troponin I (hscTnI) and other clinical variables will be associated with survival time in dogs with DMVD. Measuring hscTnI and NT-proBNP in combination will be prognostically superior to measurement of either marker alone. The rate of change of these markers will vary according to cause of death.
Client-owned dogs (n = 202) with DMVD of varying severity and age-matched healthy control dogs (n = 30) recruited from first opinion private practice.
Prospective cohort study relating clinical variables at enrollment in dogs with DMVD to survival time (all-cause, cardiac, and noncardiac mortality). Multivariable Cox regression analysis was used to identify factors associated with survival. Measurements were obtained approximately every 6 months. Repeated measures models were constructed to assess changes over time.
hscTnI, LVEDDN, heart rate, and age were independently associated with decreased survival time (all-cause mortality). Survival times were shortest in dogs in which both serum hscTnI and NT-proBNP were increased. hscTnI and NT-proBNP increased more rapidly in dogs that died of cardiac disease.
Serum hscTnI has prognostic value in dogs with DMVD. Measurement of NT-proBNP and hscTnI is prognostically superior to measuring either alone. Serial measurement strategies provide additional prognostic information.
确定与退行性二尖瓣疾病(DMVD)犬生存率降低相关的因素,将有助于更准确地进行预后评估。N 末端脑利钠肽前体(NT-proBNP)与 DMVD 犬的生存率呈负相关。在人类患者中,多标志物策略与单一标志物相比,提供了更优越的风险分层。
高敏心肌肌钙蛋白 I(hscTnI)和其他临床变量与 DMVD 犬的生存时间相关。联合测量 hscTnI 和 NT-proBNP 比单独测量任何一种标志物的预后都更优越。这些标志物的变化率将根据死亡原因而有所不同。
从第一意见私人诊所招募的患有不同严重程度和年龄匹配的健康对照组(n = 30)的患有 DMVD 的患犬(n = 202)。
前瞻性队列研究,将 DMVD 犬入院时的临床变量与生存时间(全因、心脏和非心脏死亡率)相关联。使用多变量 Cox 回归分析确定与生存率相关的因素。大约每 6 个月进行一次测量。构建重复测量模型以评估随时间的变化。
hscTnI、LVEDDN、心率和年龄与生存率降低独立相关(全因死亡率)。同时血清 hscTnI 和 NT-proBNP 升高的犬的生存时间最短。死于心脏病的犬的 hscTnI 和 NT-proBNP 增加得更快。
血清 hscTnI 在 DMVD 犬中有预后价值。测量 NT-proBNP 和 hscTnI 比单独测量任何一种标志物的预后都更优越。连续测量策略提供了额外的预后信息。